AOD-9604 and Testosterone: Interaction Profile, Safety, and Clinical Guidance

What Is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (amino acids 176-191) of human growth hormone, with an added tyrosine residue at the N-terminus. It was originally developed by Metabolic Pharmaceuticals in Australia to isolate GH's lipolytic activity without its diabetogenic or growth-promoting effects. A Phase IIb trial published in 2004 (N=300) tested oral AOD-9604 at doses of 1 mg, 5 mg, and 25 mg daily over 12 weeks in obese adults and reported modest weight loss compared to placebo, though the primary endpoint did not reach statistical significance across all dose groups [1].

In 2020, the FDA designated AOD-9604 as Generally Recognized as Safe (GRAS) for oral administration in food products at doses up to 280 mg/day [2]. This GRAS status applies only to the oral route. Injectable AOD-9604, which is the form most commonly prescribed in anti-aging and weight management clinics, is available through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The peptide has no FDA-approved drug indication. Prescribers should distinguish between the oral GRAS designation and the off-label injectable use, as the safety and pharmacokinetic profiles differ by route.

What Is Testosterone Therapy?

Testosterone replacement therapy (TRT) is FDA-approved for adult males with confirmed hypogonadism, defined by two morning serum total testosterone measurements below 300 ng/dL accompanied by signs or symptoms such as decreased libido, fatigue, or loss of muscle mass [3]. The Endocrine Society's 2018 clinical practice guideline recommends TRT only for men with unambiguously low testosterone and clear symptomatology, not for age-related decline alone [4].

Common formulations include intramuscular testosterone cypionate (100-200 mg every 1-2 weeks), topical gels (1-1.62% applied daily), and subcutaneous pellets. The FDA label for testosterone products carries a class-wide warning about increased risk of major adverse cardiovascular events (MACE), polycythemia, venous thromboembolism, and hepatotoxicity with oral methyltestosterone [3]. Polycythemia occurs in 3-7% of TRT patients and requires hematocrit monitoring every 3-6 months per AUA and Endocrine Society guidelines [4][5].

Pharmacokinetic Interaction Analysis

The likelihood of a pharmacokinetic (PK) interaction between AOD-9604 and testosterone is low based on their distinct metabolic pathways. This matters because most clinically significant drug interactions arise when two compounds compete for the same metabolizing enzyme or transporter.

AOD-9604 is a 16-amino-acid peptide. Like other small peptides, it undergoes hydrolysis by ubiquitous peptidases and proteases in plasma and tissue rather than hepatic cytochrome P450 metabolism [1]. It is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It also has no known interaction with P-glycoprotein (P-gp) or other drug efflux transporters. This metabolic profile is consistent with other synthetic peptide fragments in the same molecular-weight range.

Testosterone, by contrast, is extensively metabolized in the liver. CYP3A4 is the primary enzyme responsible for 6-beta-hydroxylation, while CYP2C9 contributes to additional oxidative pathways [3]. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) or inducers (carbamazepine, phenytoin) can alter testosterone clearance. Because AOD-9604 does not interact with CYP3A4 or CYP2C9, it is not expected to change testosterone serum concentrations, half-life, or area under the curve (AUC).

No published study has measured the PK parameters of AOD-9604 and testosterone when administered together. The absence of shared metabolic enzymes and transporter interactions makes a PK interaction unlikely on mechanistic grounds, but the formal absence of co-administration data means clinicians should document concurrent use and report any unexpected changes in testosterone trough levels.

Pharmacodynamic Overlap: Where the Real Monitoring Need Exists

While the PK interaction risk is minimal, both AOD-9604 and testosterone exert pharmacodynamic (PD) effects on adipose tissue, lean body mass, and lipid metabolism. These overlapping pathways do not constitute a drug interaction in the traditional DDI-database sense, but they create additive physiological effects that require monitoring.

AOD-9604 stimulates lipolysis and inhibits lipogenesis through a mechanism involving beta-3 adrenergic receptor signaling in adipocytes [1]. Preclinical studies in Zucker fatty rats demonstrated reduced adipose tissue mass without affecting IGF-1 levels or glucose homeostasis. Testosterone also reduces fat mass, particularly visceral adiposity, through androgen-receptor-mediated suppression of lipoprotein lipase activity and increased beta-oxidation of fatty acids [6]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement in men aged 45-80 with hypogonadism and cardiovascular risk did not increase MACE incidence versus placebo (HR 0.99; 95% CI 0.81-1.21), but did confirm the established effect of TRT on body composition [7].

When both compounds are used concurrently, the additive lipolytic effect could accelerate fat loss. That sounds desirable. The clinical concern, however, is that rapid lipolysis may transiently worsen lipid profiles by flooding the circulation with free fatty acids, potentially raising LDL cholesterol or triglycerides in susceptible patients. Testosterone itself has a documented effect of reducing HDL cholesterol by 5-10% in TRT patients [4]. No published data quantify the combined lipid effect of AOD-9604 and testosterone, so clinicians should obtain fasting lipid panels at baseline and at 6 and 12 weeks after starting the combination.

Polycythemia Risk: Testosterone's Primary Hematologic Concern

Polycythemia is the most common laboratory adverse effect of TRT. Testosterone stimulates erythropoiesis through direct stimulation of erythroid progenitor cells and suppression of hepcidin, the peptide hormone that regulates iron absorption [8]. The Endocrine Society guideline recommends withholding TRT if hematocrit exceeds 54% and resuming at a lower dose once hematocrit falls below 50% [4].

AOD-9604 has no known effect on erythropoiesis. The original Phase IIb data and subsequent safety reviews did not report changes in hemoglobin, hematocrit, or red blood cell indices [1]. Full-length growth hormone can increase red cell mass, but AOD-9604 was specifically designed to exclude the somatotropic domain responsible for IGF-1-mediated erythropoietic signaling. For this reason, adding AOD-9604 to a TRT regimen is not expected to compound the polycythemia risk. Standard hematocrit monitoring protocols for TRT should still be followed. The American Urological Association (AUA) recommends checking hematocrit at 3-6 months after starting TRT and then annually [5].

Cardiovascular Risk Considerations

Both testosterone and growth hormone fragments have been subjects of cardiovascular safety scrutiny. The FDA added a class-wide cardiovascular warning to testosterone products in 2015 based on observational data suggesting increased MI and stroke risk in older men and those with pre-existing cardiovascular disease [3]. The TRAVERSE trial subsequently provided reassurance that TRT does not increase MACE in hypogonadal men with or at high risk for cardiovascular disease over a median follow-up of 33 months [7].

AOD-9604 cardiovascular data are limited. Preclinical studies did not identify cardiotoxicity. The oral GRAS assessment reviewed by the FDA's Independent Expert Panel did not flag cardiovascular adverse events at doses up to 280 mg/day [2]. However, the GRAS review was conducted for oral food-grade use, not injectable pharmaceutical use at the subcutaneous doses (250-500 mcg/day) commonly prescribed in clinic settings.

Clinicians prescribing both agents should obtain a baseline cardiovascular risk assessment. For men over 45 with established atherosclerotic cardiovascular disease or multiple risk factors, the decision to combine AOD-9604 with TRT should be weighed against the limited long-term safety data for the peptide. Blood pressure monitoring at each visit is appropriate, as testosterone can cause fluid retention, and any additive body-composition changes may alter metabolic risk markers.

Monitoring Protocol for Combined Use

A structured monitoring approach reduces the risk of missing clinically significant changes when AOD-9604 and testosterone are used together.

Baseline (before starting combination):

• CBC with differential (hematocrit is the key value)
• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Comprehensive metabolic panel (hepatic and renal function)
• Total and free testosterone, SHBG
• PSA (men over 40)
• Fasting glucose and HbA1c
• Body composition assessment (waist circumference at minimum)

Follow-up at 6 weeks:

• Hematocrit
• Fasting lipid panel
• Testosterone trough level (to ensure TRT is dosed appropriately)

Follow-up at 12 weeks and every 3-6 months thereafter:

• Full CBC
• Fasting lipid panel
• Testosterone trough
• PSA
• Clinical assessment of injection-site reactions (for subcutaneous AOD-9604)

If hematocrit exceeds 54%, testosterone dose should be reduced or therapy held per Endocrine Society guidance [4]. If LDL rises by more than 30 mg/dL from baseline or triglycerides exceed 500 mg/dL, evaluate whether the AOD-9604-driven lipolysis is contributing and consider pausing the peptide.

Injection-Site and Practical Considerations

Patients using subcutaneous AOD-9604 alongside intramuscular or subcutaneous testosterone should rotate injection sites to minimize local reactions. AOD-9604 is typically administered subcutaneously in the abdominal region. Testosterone cypionate is given intramuscularly in the gluteal or deltoid muscle, though subcutaneous injection of testosterone cypionate has gained acceptance and is supported by PK data showing comparable absorption [9].

Timing of injections does not appear pharmacologically relevant given the absence of PK interaction. Patients may administer both on the same day. AOD-9604 is often dosed in the morning on an empty stomach based on the rationale (derived from GH physiology) that fasting-state lipolysis may be augmented, though no controlled trial has confirmed this timing-dependent effect for AOD-9604 specifically.

Storage requirements differ. Reconstituted AOD-9604 must be refrigerated at 2-8°C and used within 28 days. Testosterone cypionate in its oil-based formulation is stored at room temperature (20-25°C) and does not require refrigeration [3].

Regulatory and Compounding Considerations

AOD-9604's regulatory status is unusual and worth clarifying for patients. It is not an FDA-approved drug. Its GRAS designation applies only to oral use as a food ingredient [2]. Injectable AOD-9604 is produced by compounding pharmacies under Section 503A (patient-specific prescriptions) or 503B (outsourcing facilities). The quality and purity of compounded peptides can vary between pharmacies. Clinicians should verify that their compounding source follows Current Good Manufacturing Practice (cGMP) standards and provides certificates of analysis showing peptide purity greater than 98% and endotoxin levels within USP limits.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. It requires a DEA-registered prescriber and cannot be refilled more than five times or dispensed more than six months after the date of the prescription [3]. Combining a compounded peptide with a controlled substance in the same treatment plan introduces documentation requirements: both agents should be clearly listed in the medical record with clinical rationale for concurrent use.

When to Avoid the Combination

The combination of AOD-9604 and testosterone should be avoided or used with extreme caution in certain patient populations:

• Polycythemia vera or baseline hematocrit above 50%: Testosterone will likely push hematocrit higher. Adding any agent that alters body composition may complicate monitoring.
• Active or history of hormone-sensitive malignancy: Testosterone is contraindicated in men with known breast or prostate cancer [4]. AOD-9604's safety in cancer patients has not been studied.
• Severe hepatic impairment: While AOD-9604 is not hepatically metabolized, testosterone clearance is reduced in liver disease, and monitoring becomes more complex.
• Pregnancy or women who may become pregnant: Testosterone is FDA Pregnancy Category X. AOD-9604 has no reproductive toxicology data in humans.
• Patients under 18: Neither agent has pediatric safety or efficacy data for this indication.

Clinicians considering this combination should document the risk-benefit analysis in the patient's chart and obtain informed consent that includes the off-label and compounded nature of AOD-9604.